GeneLink Signs Agreement with National Distributor
October 27, 2004

MARGATE, NJ, October 27, 2004 – GeneLink BioSciences, Inc. (OTCBB:GNLK) the genetic biosciences company announced it has entered into a distribution agreement with Rave Reviews, LLC., to offer GeneLink's patented DNA collection system and Dermagenetics™ line of skin care products to its customers for the spa industry.

Rave Reviews is a national distributor in the United States to a variety of spas, including Resort and Day Spas, Medi Spas and Cruise Lines spas.

John H. Souza, president of Rave Reviews, says, "We are excited to be teaming with GeneLink to launch the revolutionary Dermagenetics® brand to the spa industry. This is the first and only completely customized humanistic skin-care, genetically matched to each client's DNA (Dermagenetics) profile." "These products are destined to become an extraordinary new profit center for the spa industry," he adds.

"We will be launching the Dermagenetics® products at the International Spa Convention in Las Vegas on November 7th and sales will begin immediately" says John DePhillipo, GeneLink's CEO. "We are delighted to have partnered with a company like Rave Reviews, which has an impressive proven track record, to handle our product distribution as we move forward."

GeneLink is a pioneer genetic biosciences services/products company that has developed a proprietary method for "genetic profiling" (patents pending) and is licensing this breakthrough technology to companies that market or manufacture products for the $100 billion plus skin care, nutritional supplement and wellness industries. GeneLink has developed a proprietary genetic test (Dermagenetics™) and matching personal care products to be distributed in various marketing channels.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.